Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
Laura Fisher
Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK. E-mail: advances-rsc@rsc.org
First published on 27th January 2021
Abstract
Retraction of ‘MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells’ by Guimin Chen et al., RSC Adv., 2019, 9, 21139–21146, DOI: 10.1039/C8RA10224D.
The Royal Society of Chemistry hereby wholly retracts this RSC Advances article due to concerns with the reliability of the data. The images in the article were screened by an image integrity expert. All of the western blot panels have no visible background and all look very regular in shape, implicating that they may not be genuine. The GAPDH control panel in Fig 3E is duplicated in Fig 4A, but these represent different experiments. Furthermore, the western blots and many other features of the article were found to be unexpectedly similar to western blots and features in other papers with no overlapping authors.
The authors were asked to provide the raw data for this article, but did not respond. Given the significance of the concerns about the validity of the data, and the lack of raw data, the findings presented in this paper are not reliable.
The authors have been informed but have not responded to any correspondence regarding the retraction.
Signed: Laura Fisher, Executive Editor, RSC Advances
Date: 15th January 2021
| This journal is © The Royal Society of Chemistry 2021 |